Tessa Brabander

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Tessa Brabander, Wouter A. van der Zwan, Jaap J.M. Teunissen et al. · Clinical Cancer Research · 2017 · 580 citations

Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors

Wouter T. Zandee, Tessa Brabander, Anela Blažević et al. · The Journal of Clinical Endocrinology & Metabolism · 2018 · 132 citations · Full text

Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours

Wouter A. van der Zwan, Tessa Brabander, Boen L.R. Kam et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 130 citations · Full text

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ]Octreotate

Esther I. van Vliet, Casper H.J. van Eijck, Ronald R. de Krijger et al. · Journal of Nuclear Medicine · 2015 · 120 citations · Full text

Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE

Wouter T. Zandee, Richard A. Feelders, Daan A. Smit Duijzentkunst et al. · European Journal of Endocrinology · 2019 · 76 citations · Full text